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 Objective To review the epidemiology, pathophysiology, clinical 
manifestations, diagnosis, and treatment of gouty arthritis of the 
hand and wrist, with a focus on the surgical aspects.
Data sources and extraction Electronic databases including MEDLINE, PubMed, and the 
Cochrane library were searched with the key words of “gouty 
arthritis”, “hand”, “wrist”, and “surgical”. 
 Study selection A total of 55 articles were selected for inclusion in this review.
 Data synthesis There is no existing study for the overall prevalence of gout 
in Asia, though one study showed that it was 3.1% in Taiwan. 
Its pathophysiology entails hyperuricaemia, trauma, lower 
temperatures, and previous diseases. Gouty arthritis of hand 
and wrist presents as acute wrist pain, subcutaneous or 
peritendinous tophi, tenosynovitis, entrapment neuropathy, 
tendon rupture, or even bone destruction. Demonstration of 
negatively birefringent crystals in the absence of organisms and 
a normal white cell count in synovial fluid confirm the diagnosis. 
Medical treatment including non-steroidal anti-inflammatory 
drugs, colchicines, allopurinol, uricosuric agents, and lifestyle 
modifications remain the mainstay of treatment. Surgical 
treatment options for tophaceous gout involve decompression 
by aspiration, incision and drainage, tenosynovectomy, shaving 
procedures, and complex surgical approach.
 Conclusion While medical treatment remains the mainstay of treatment for 
gouty arthritis of the hand and wrist, 5% of patients may not 
respond. In this group, surgery is often performed in advanced 
stages, but yields less-than-satisfactory outcomes. Gouty arthritis 
is difficult to treat when it starts to cause stiffness and deformities. 
Although more studies are needed to evaluate the outcomes, the 
authors suggest that one possible solution is pre-emptive surgery. 
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Gout is an ancient medical disorder recognised since the time of Hippocrates.1 Its 
prevalence in western populations was 1.4%.2 The overall male-to-female ratio was 3.6:1. 
The prevalence peaked in men between the ages of 75 and 84 years (7.3%), while in women 
its prevalence continued to rise beyond the age of 85 years (being about 2.8%). The 
epidemiology of gout is difficult to quantify precisely as there are variations in methodology 
between studies, especially in terms of case definitions. One paper concluded that the 
prevalence of gout in Taiwan to be 3.1%,3 but this cannot be generalised to Asia. Gouty 
arthritis is an intense and painful inflammatory response elicited by subcutaneous or 
bursal deposits of monosodium urate (MSU) crystals, which commonly manifest as a 
monoarticular arthropathy of the first metatarsophalangeal joint, better known as podagra. 
In contrast to podagra, only a few articles review gouty arthritis of the hand and wrist. This 
paper reviews the less prominent, but by no means less important, involvement of gouty 
arthritis in the hand and wrist, with a focus on currently available surgical interventions.
Methods
Multiple online electronic databases including MEDLINE, PubMed, and the Cochrane 
library were used for article collection. The key words searched included: “gouty 




were included. Epidemiology, pathophysiology, 
clinical manifestations, diagnosis, and treatment 
were reviewed. Bibliographies of chosen articles 
were screened for additional relevant articles not 
discovered through database searches.
Pathophysiology
Hyperuricaemia is an important component in the 
development of gout. It is defined as a serum uric 
acid level of more than 7.0 mg/dL (0.42 mmol/L) in men 
and 6.0 mg/dL (0.36 mmol/L) in women.4 One study 
showed that 18.8% of patients with hyperuricaemia 
develop gout in 5 years. The only predictor of 
gout at baseline was the uric acid level, but other 
contributing factors included alcohol consumption, 
diuretics use, and excess weight gain; all of which 
increased the risk of a gouty attack in patients with 
hyperuricaemia.5
 Hyperuricaemia can be the result of 
overproduction or underexcretion of uric acid. For the 
production of uric acid, the source of urate either may 
be exogenous (ingestion of purine-containing food) 
or endogenous (synthesis of purine nucleotides). 
For excretion of uric acid, during evolution, there 
was loss of the enzyme, uricase, which oxidised uric 
acid (to a highly soluble compound, allantoin).6 As a 
result, renal excretion became an important pathway 
of uric acid elimination; 80 to 90% of the patients with 
hyperuricaemia or gout are underexcretors.7
 Other contributing factors besides hyper-
uricaemia include: trauma, lower temperatures, and 
previous diseases.8 The first metatarsophalangeal 
joint is often affected in gout, partly because it is a 
site of mechanical stress and prone to minute trauma. 
Lower temperature favours crystal deposition.9 This 
explains why the helix of ear and foot are often 
affected. Previous disease, such as osteoarthritis 
in the fingers, can increase the chance of crystal 
deposition in the previously diseased joint.8
 The mechanism by which MSU crystals cause 
gouty arthritis entails two phases. The first requires 
phagocytic cells such as monocytes to internalise MSU 
crystals and activate c complex called inflammasome, 
followed by the release of interleukin (IL)–1β. The 
second involves an inflammatory response driven 
by IL-1R, resulting in the production of chemokines 
and inflammatory mediators. All of these eventually 
result in a neutrophil influx into the joints, which is 
the characteristic of gouty inflammation.10 
 There are four different phases in gout. They 
include: asymptomatic hyperuricaemia, acute gouty 
arthritis, intercritical gout, and chronic tophaceous 
gout.11 During the intercritical gout period, the joints 
appear to return to normal between attacks.12 The 
disease progresses to chronic tophaceous gout if 
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and usually develops after 10 years or more of acute 
intercritical gout.13 Crystallographic analyses show 
that tophi consist of macroscopic collections of MSU 
crystals.14
Clinical manifestations
Gouty arthritis of the wrist usually manifests as 
acute wrist pain and subcutaneous or peritendinous 
tophi.15,16 It may progress to destructive bone lesions 
and ligament disruption. It is usually painful with the 
presence of acute tophi. It is believed that the pain 
in a tophaceous deposit is caused by the increasing 
tension following rapid deposition of urate crystals 
in a semi-fluid state.17 The tophi are often associated 
with degenerative changes of the involved joint.18
 Periarticular or articular tophi (Fig) in the 
fingers cause limitation of finger motion. Mallet 
finger, boutonniere and hyperextension deformities 
may result when there is loss of balance between 
the flexor and extensor-tendon mechanisms.19 The 
frequency of tophaceous gout in carpal tunnel 
syndrome was reported to be 0.6%.20 The median 
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nerve is compressed due to increased volume of 
carpal tunnel contents by the tophaceous material.21 
Tendon involvement can lead to tenosynovitis, 
entrapment neuropathy, or even tendon rupture.22 
Involvement of tendons can also present as pain and 
local warmth, which is difficult to distinguish from 
infection.23
Diagnosis
Arthrocentesis and synovial fluid analysis remains 
the gold standard for diagnosis of gouty arthritis. 
Pathological samples obtained from biopsy of the 
synovium, tendon, ligament, and tophi should be 
transported in alcohol instead of formalin so as to 
prevent MSU crystal degradation.24 Gouty arthritis 
is confirmed with the presence of negatively 
birefringent crystals, an absence of organisms, and 




In the acute attack, rest and topical ice are effective.26,27 
Oral non-steroidal anti-inflammatory drugs (NSAIDs) 
and colchicine are the drugs used most often.13 Oral 
colchicine is the conventional drug for gout and is 
most effective during the first 12 to 24 hours of a 
gouty attack.13 A recent study28 showed that low-dose 
oral colchicine (1.2 mg followed by 0.6 mg 1 hour 
later) is as effective as high-dose oral colchicine (1.2 
mg followed by 0.6 mg every hour for 6 hours), but 
gave rise to lower rates of diarrhoea, vomiting, and 
other side-effects. Although NSAIDs are the drugs 
of choice in gouty arthritis in patients without other 
co-morbidities, they should be used cautiously in 
patients with peptic ulcer disease,29 renal disease,30 
and in those receiving anti-coagulants.13 Intra-
articular and systemic corticosteroids are other 
options.31,32
 Lowering serum urate concentrations to levels 
of less than 6.0 mg/dL (360 μmol/L) may prevent gout 
and reduction to less than 5.0 mg/dL may be necessary 
to resorb tophi.33 Lifestyle and dietary modification 
including reduction of alcohol intake,34 weight 
reduction in men,35 decreased intake of purine-
rich foods of animal origin,36 and increased dairy 
food consumption can lower serum urate level.37 In 
2006, the European League Against Rheumatism38 
recommended that allopurinol should be started at a 
low dose (100 mg daily), especially for those with renal 
impairment. The dose should be increased by 100 
mg every 2 to 4 weeks if required. Uricosuric agents, 
such as probenecid, are used in patients with normal 
renal function, but 4 times daily administration 
is advocated for full therapeutic efficacy.39 A new 
non-purine xanthine oxidase inhibitor,40 febuxostat, 
has comparative efficacy to allopurinol (40 mg 
daily of febuxostat is comparable to 300 mg daily of 
allopurinol).41 A newly developed uricase attached to 
a polyethylene glycol moiety is currently undergoing 
trials. This drug breaks down uric acid, converting it 
to allantoin, which is highly soluble. It can be used 
as a ‘debulking’ agent in severe tophaceous gout, but 
its residual immunogenic properties can render the 
disease refractory to ongoing use.42
Surgical treatment
Despite the use of optimal medical treatment, 5% of 
patients may not respond and some may progress 
to tophaceous stage.43 The traditional indications for 
surgery are15,19: (1) functional, which includes excision 
to allow wearing of clothing and gloves, restoration 
of motion, and joint stability; (2) symptomatic, which 
includes reduction of pain, decompression of nerves, 
control of infection, discharging sinus, and skin 
ulceration; and (3) cosmetic restoration, especially 
for tophaceous gout in the hand and wrist.
 Although various methods can be used to 
operate on patients with gouty arthritis in the hand, 
some general principles are the same. The tissues, 
especially the skin overlying a large subcutaneous 
tophi, should be handled gently because it may 
have impaired vascular supply.44 Sharp dissection 
and curettage are commonly employed for most 
infiltrative lesions involving tendon and joint 
capsules in the hand. Most of the time, the tendons 
can be kept intact by just shaving the tophus down to 
the original size of the tendon, followed by medical 
management which causes slow absorption of the 
remaining tophus.15 Every effort should be directed 
at preservation of hand function. However, if there 
is advanced tophaceous infiltration of the tendon, 
resection followed by primary repair or subsequent 
tendon transfer can be performed.45
 If the involved areas are clean and have intact 
covering skin, primary closure can be achieved 
FIG. Gouty tophi in the thumb
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following debridement, as the wounds are likely 
to heal well.46 The wounds should be closed with 
a minimal number of interrupted subcutaneous 
sutures, since a large number of subcutaneous 
sutures jeopardise the network of blood vessels 
just beneath the skin overlying any tophus.43 
Frequent irrigation of the wound in the operation is 
recommended. Not only does this wash away urates, 
it also prevents drying of the wound and tissue 
damage. Furthermore, the crystals are moderately 
hygroscopic and tend to dry out the surrounding 
tissues during curettage.43 Since the solubility of 
urate has a two-fold rise between 25°C and 37°C,47 
warm normal saline irrigation can theoretically 
decrease the rate of clogging, and therefore increase 
the efficiency of urate removal. 
 The method chosen for removal of tophi 
depends on their consistency. For soft and fluctuant 
tophi, Cassagrande15 recommended decompression 
by aspiration or incision, whilst drainage was the 
best option. This is because primary closure of 
the fluctuant areas by surgery delays healing and 
infrequently may exacerbate gout. 
 For hard tophi, surgery is often needed for 
removal. Surgical procedures used to remove 
tophaceous deposits involve tenosynovectomy, 
shaving, and other complex surgical approaches.
 Tenosynovectomy involves debridement of 
tophi, and release of relatively unimportant but 
heavily infiltrated tendon sheaths. For important 
tendon sheath, removal can cause bow-stringing of 
the corresponding tendon. However, the tendon 
could be shaved to improve gliding between 
the residual tendon and the tendon sheath. It is 
indicated for tendons that are heavily infiltrated by 
the tophaceous substance and loss of active digital 
motion but without overlying skin ulcerations. The 
procedure can rapidly improve the range of motility 
with a small chance of postoperative complications. 
Its limitation is that it is associated with a significant 
risk of tendon adhesions, which may be reduced by 
early physiotherapy.48 The shaving procedure involves 
a shaver that performs oscillating movements at high 
speed. This is faster and more efficient than manual 
curetting movements. In a study of 32 patients, 
each tophaceous lesion was removed in less than 
15 minutes with uneventful postoperative recovery, 
except that two patients endured recurrent acute 
attacks of gouty arthritis that were controlled by 
colchicine and analgesics.49 The authors made no 
mention of any flexor tendon involvement nor did 
they state whether the procedure was feasible with 
carpal tunnel syndrome. The shaving procedure is 
indicated if tophaceous deposits are not excessive 
and in the absence of significant skin ulceration.48 
This less-invasive technique tends to spare the skin. 
Its limitation is that it cannot be performed where 
there are important nerves and tendons, (eg proximal 
interphalangeal finger joints), since it is a blind 
procedure and the chance of injuring surrounding 
structures is relatively high. Based on their 
experience of 29 cases, Tripoli et al48 recommended 
that a complex surgical approach should be the first-
choice operation for gouty tophi. This involves an ‘S-
shaped incision’ overlying the tophaceous deposits 
and excision of the gouty tophi after identification 
of important structures. Its advantages are: better 
exposure of the important structures, better range 
of motion and cosmesis, less pain, and a prolonged 
disease-free period. From their experience, they 
recommend this complex surgical approach as the 
treatment of first choice. The indications include: 
unremitting single joint pain uncontrolled despite 
drug treatment, infection, significant deformity, and 
joint stiffness. The limitation of this approach is that 
it needs considerable expertise. The handling of soft 
tissue entails careful removal, while not compromising 
skin circulation. Preoperatively, the patient must 
be educated regarding postoperative management 
to facilitate an improved outcome. Postoperatively, 
wound and joint pain are common but should not 
be allowed to hinder mobilisation exercise, lest the 
mobility of hand becomes much worse. Moreover, 
postoperative wound and joint pain are temporary 
and after wound healing its extent diminishes to 
levels less than those in the preoperative state.
 Gouty tophi also occur over interphalangeal 
joints. In tophaceous gout involving proximal 
interphalangeal joints, tophectomy and extensor 
mechanism reconstruction are performed if medical 
treatment fails. Tophectomy should be carried out 
earlier in patients who are allergic to allopurinol 
or who have renal disease.50 For tophaceous gout 
involving the distal interphalangeal joint, Mudgal18 
recommended aspiration through neighbouring 
uninvolved skin, in order to overcome delayed wound 
healing. Ideally, arthrodesis should be considered 
for persistently symptomatic and unstable distal 
interphalangeal joints.
 Hydrosurgery was described by Vanwijck et 
al51 in 2010. It removes target tissue and creates a 
smoother, less irregular wound surface, making it 
more feasible to receive a skin graft. Its pressurised 
pulsatile lavage effect is believed to reduce the 
bacterial load and prevent the diffusion of microbial 
contaminants deeper into the wound.52 Lee et al53 
reported two cases of subcutaneous tophaceous gout 
on the lateral malleolar area with successful skin graft 
and local flap coverage after hydrosurgery. Studies 
have shown that the hand usually has better wound 
healing than the foot, due to its better blood supply.49 
The authors of that report therefore believed that 
this technique produces better results when applied 





Medical treatment remains the mainstay for managing 
gouty arthritis of the hand and wrist. It is very 
effective, especially in those with occasional attacks. 
In patients with repeated gouty attacks and tophi, 
urate-lowering therapy is indicated. However, about 
5% of the patients may not respond and this group 
may present to orthopaedic surgeons under three 
categories: infection of the affected area; poor hand 
function (operation requested to improve function); 
or intolerable deformity (operation requested for 
cosmesis). When infection is present, the primary 
goal is to control the infection, so the vital structures 
including skin and tendons in the hand may have to be 
sacrificed. However, severe infection is uncommon 
in tophaceous gout, because tophaceous material 
is generally regarded as bacteriostatic.19 Regarding 
patients with deformity and poor hand function, 
they usually present to the orthopaedic surgeons 
late, and the disease is so advanced and severe that 
vital structures in the hand may need to be removed. 
In advanced gout with large tophaceous deposits, 
there is high risk of delayed postoperative wound 
healing because of the poor circulation to overlying 
skin. Inadequate removal of uric acid deposits causes 
uric acid to seep through the wound, which also 
contributes to delayed wound healing. Since the 
tophaceous deposits in advanced disease are large, 
adequate removal often entails removal of affected 
vital structures including tendons. As a result, there 
may be no improvement of hand function after 
operation for advanced disease. On the other hand, 
cosmesis cannot be restored without an operation. 
The orthopaedic surgeons therefore always face a 
dilemma in deciding whether or not to operate on 
these patients. In mitigating this dilemma, in this 
group of patients there is a need for the timing of 
surgery to be reconsidered. 
 The hand and wrist are functionally very 
important for humans to perform daily activities. 
Although the traditional indications for surgery 
in gouty arthritis involve restoration of function, 
symptomatic relief and cosmetic restoration, the 
authors propose that a fourth indication, namely 
‘pre-emptive surgery’, should be added. For patients 
who have repeated attacks of gouty arthritis, a few 
tophaceous deposits and mild stiffness of the 
joint but failure of medical treatment, there is a 
high chance of disease progression. Operations 
performed after bone, joint, tendon or skin 
involvement, have a high morbidity, especially 
delayed wound healing. Moreover, sometimes tophi 
can grow silently for years without episodes of acute 
gout,12 which gives a false impression that the disease 
is controlled. Thus, one study showed that there 
is frequent hand function impairment in patients 
with chronic tophaceous gout, as the deposits 
may damage the joint, causing synovitis and/or a 
mechanical obstruction to joint movement.54 Such 
gouty arthritis may ultimately require a debulking 
operation. The authors recommend that once joint 
stiffness has developed as a result of gouty deposits 
infiltrating into the tendon and joint area, debulking 
surgery should be performed. This may retard 
progress of the gouty arthritis and decrease the 
chance of gouty tophi eroding vital structures in the 
hand and wrist. Otherwise (in advanced disease), 
it might only be possible to restore minimal hand 
function by surgery.
 Surgery for advanced stages of gouty arthritis 
has a lot of disadvantages. Curettage and debulking 
of large tophi is time-consuming. Besides, the crystals 
are hard and there is fibrotic tissue around the tophi, 
making manual curettage inefficient. In addition, 
large tophi cause local ischaemia to surrounding skin. 
As a result, there is a risk of necrosis of the overlying 
skin, if skin incisions are inappropriate.55 Kumar and 
Gow56 found that in surgery for gouty tophi, 53% of 
patients experienced delayed wound healing. This 
study was quoted in the literatures as the major 
reason of reserving surgery for the advanced-staged 
gout. However, prior to surgery, the majority of their 
patients (67%) had infected or ulcerated tophi. We 
believe that if earlier surgery were to be performed, 
these patients would not have had infected or 
ulcerated tophi, and resulted in better postoperative 
recovery. The advantages of pre-emptive surgery 
include better wound healing as there is no skin 
infiltration. The postoperative hand function will also 
be better as there is less tendon infiltration.
 Throughout the years, various surgical 
techniques for gouty arthritis, including 
tenosynovectomy, shaving procedures, a complex 
surgical approach, and hydrosurgery have been 
developed. All these aim to remove the gouty 
deposits more efficiently. Yet the results of surgical 
management of gouty arthritis cannot improve if the 
operation is performed at suboptimal time.
 One potential selection bias for this review is 
that it only involved literature covering the past 60 
years. Earlier literature was not reviewed. However, 
most of the principles discussed here only appeared 
in later review articles. Also, with rapid developments 
in the field of medicine, newer evidence could have 
more impact on our clinical practice.
 Finally, while a lot of effort has gone into the 
development of surgical techniques, optimal timing 
for such operations should be reconsidered. Earlier 
operations for gouty arthritis can reduce the technical 
difficulties and improve the functional outcomes. 
With the ideas proposed in this article, it is hoped 
that surgery will not become the last defence in 
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